Inclusion Criteria:

          -  - Histologically proven colorectal adenocarcinoma without RAS mutation

          -  Confirmed, non-resectable metastatic disease (Stage IV)

          -  No prior chemotherapy except perioperative or adjuvant chemotherapy discontinued for
             more than 12 months

          -  At least one measurable metastasis according to the RECIST v1.1 criteria

          -  Age ≥ 18 years

          -  WHO ≤ 2

          -  Neutrophils > 1500 /mm3, platelets> 100 000/mm3, Hb > 9 g/dL

          -  Creatinine clearance > 50 mL/min according to the MDRD formula

          -  Serum bilirubin < 25 µmol/L, AST, ALT, Alk Phos < 2.5 x ULN or < 5 x ULN in case of
             liver metastases

          -  PT > 60%, albumin ≥ 25g/L

          -  Estimated life expectancy ≥ 3 months

          -  Patient affiliated to a social security scheme

          -  Patient informed and informed consent form signed

        Exclusion Criteria:

          -  - Presence of uncontrolled symptomatic brain metastases

          -  RAS mutation (KRAS or NRAS mutation)

          -  Patient taking warfarin. If treated with anticoagulant at the indicated effective
             dose, this must be replaced with low molecular weight heparin before inclusion

          -  Known DPD deficiency

          -  Peripheral neuropathy > 1 (NCI CTCAE v4.0)

          -  Patient with interstitial pneumonitis or pulmonary fibrosis

          -  History of chronic diarrhoea or inflammatory disease of the colon or rectum, or
             obstruction or sub-obstruction during symptomatic treatment

          -  Poorly controlled chronic skin disease

          -  Any known specific contraindication or allergy to the medicinal products used in the
             study

          -  Patient simultaneously included in another clinical trial involving an investigational
             drug (example: chemotherapy, targeted therapy, immunotherapy)

          -  Arterial hypertension not controlled by medical treatment (Systolic BP ≥ 160 mmHg
             end/or diastolic BP ≥ 90 mmHg)

          -  Any progressive pathology not stabilised over the past 6 months: hepatic failure,
             renal failure, respiratory failure

          -  The following conditions in the 6 months prior to inclusion: myocardial infarction,
             severe/unstable angina, coronary artery bypass surgery, congestive heart failure NYHA
             class II, III or IV, stroke or transient ischaemic attack

          -  Patient who has received a transplant, is seropositive for HIV, hepatitis B or
             hepatitis C or has other immunodeficiency syndromes

          -  History of malignant pathologies during the past 5 years except basal cell carcinoma
             of the skin or cervical carcinoma in situ, properly treated

          -  QT/QTc interval > 450 msec for men and > 470 msec for women

          -  K+ < LNL, Mg2+ < LNL, Ca2+ < LNL

          -  Lack of effective contraception in patients (men and/or women) of childbearing age,
             pregnant or breastfeeding women, women of childbearing age who have not had a
             pregnancy test

          -  Persons in custody or under wardship

          -  Impossibility of undergoing medical monitoring during the trial for geographical,
             social or psychological reasons